Skip to main content
Menu
US

AlphaLISA SureFire Ultra Human Total TREM2/DAP12 Complex Detection Kit, 500 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human Total TREM2/DAP12 Complex assay is a sandwich immunoassay for quantitative detection of total TREM2/DAP12 Complex in cellular lysates using Alpha Technology.

For research use only. Not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Feature Specification
Application Protein-Protein Interaction
Sample Volume 10 µL

The AlphaLISA™ SureFire® Ultra™ Human Total TREM2/DAP12 Complex assay is a sandwich immunoassay for quantitative detection of total TREM2/DAP12 Complex in cellular lysates using Alpha Technology.

For research use only. Not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Product Variants
Unit Size: 500 Assay Points
Part #:
ALSU-TTRMDP-A500
List Price
USD 2,346.00
Unit Size: 10,000 Assay Points
Part #:
ALSU-TTRMDP-A10K
List Price
USD 14,270.00
Unit Size: 50,000 Assay Points
Part #:
ALSU-TTRMDP-A50K
List Price
USD 46,060.00
Unit Size: 100 Assay Points
Part #:
ALSU-TTRMDP-A-HV
List Price
USD 694.44

Overview

The TREM-2 (Triggering Receptor Expressed on Myeloid Cells 2) family of receptors regulates the immune system's various cell types, such as neutrophils, monocyte/macrophages, microglia, and dendritic cells. TREM-2 requires the adaptor protein DAP12 for downstream signaling. Human cerebrospinal fluid (CSF) has been shown to include soluble TREM-2, which has been reported to be increased in people with multiple sclerosis and other inflammatory neurological illnesses compared to those without such conditions.

The AlphaLISA SureFire Human Total TREM2/DAP12 Complex is a sandwich immunoassay for the quantitative detection of total TREM2/DAP12 complex in cellular lysates, using Alpha Technology.

Formats:
  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.
AlphaLISA SureFire Ultra kits are compatible with:
  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies
Alpha SureFire kits can be used for:
  • Cellular kinase assays
  • Receptor activation studies
  • Screening

Specifications

Application
Protein-Protein Interaction
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Lysis Buffer Compatibility
Lysis Buffer
Product Group
Kit
Sample Volume
10 µL
Shipping Conditions
Shipped in Blue Ice
Target
TREM2/DAP12
Target Class
Binding Assay
Target Species
Human
Technology
Alpha
Therapeutic Area
Neuroscience
Unit Size
500 Assay Points

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-3 of 3 Resources
Guide Icon
Guide
AlphaLISA SureFire Ultra assay optimization

This guide outlines further possible optimization of cellular and immunoassay parameters to ensure the best possible results are...

Infographic Icon
Infographic
Neurodegeneration and associated diseases

See this infographic for a summary on the key diseases related to neurodegeneration, associated risk factors, and specific cell...

Whitepaper Icon
Whitepaper
Shifting the treatment paradigm: the promise of gene therapy for neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s, are complex disorders that affect millions...

Scroll Icon